Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218

NCT03672188 is registered in ClinicalTrials.gov with Vir Biotechnology, Inc. as lead sponsor.

NCT NCT03672188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03672188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
Lead sponsor
Vir Biotechnology, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 14, 2018
Completion date
September 3, 2020
Enrollment
82 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b